Mucosal parainfluenza virus-vectored vaccine against Ebola virus replicates in the respiratory tract of vector-immune monkeys and is immunogenic

Virology

Volumn 399, Issue 2, 2010, Pages 290-298

  Bukreyev, Alexander A ^a   DiNapoli, Joshua M ^a   Yang, Lijuan ^a   Murphy, Brian R ^a   Collins, Peter L ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Antibody; Ebola; Immunity; Immunogenicity; Intranasal vaccination; Monkey; Mucosal vaccination; Vaccine; Vaccine vector; Virus

Indexed keywords

NEUTRALIZING ANTIBODY; VIRUS GLYCOPROTEIN; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; EBOLA HEMORRHAGIC FEVER; EBOLA VIRUS; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOGENICITY; IN VITRO STUDY; NONHUMAN; PARAINFLUENZA VIRUS 3; PRIORITY JOURNAL; RESPIRATORY SYSTEM; RHESUS MONKEY; VIRION; VIRUS INFECTIVITY; VIRUS NEUTRALIZATION; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS SHEDDING;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CELL LINE; EBOLA VACCINES; EBOLAVIRUS; HEMORRHAGIC FEVER, EBOLA; MACACA MULATTA; PARAINFLUENZA VIRUS 3, HUMAN; RESPIRATORY SYSTEM; VIRAL ENVELOPE PROTEINS; VIRUS REPLICATION; VIRUS SHEDDING;

ANIMALIA; EBOLA VIRUS; HUMAN PARAINFLUENZA VIRUS 3; MACACA MULATTA; PARAINFLUENZA VIRUS; PRIMATES;

EID: 77249161128     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2010.01.015     Document Type: Article

References (43)

1. Barouch D.H., Pau M.G., Custers J.H., Koudstaal W., Kostense S., Havenga M.J., Truitt D.M., Sumida S.M., Kishko M.G., Arthur J.C., Korioth-Schmitz B., Newberg M.H., Gorgone D.A., Lifton M.A., Panicali D.L., Nabel G.J., Letvin N.L., and Goudsmit J. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J. Immunol. 172 10 (2004) 6290-6297
2. Boukhvalova M.S., Prince G.A., and Blanco J.C. Respiratory syncytial virus infects and abortively replicates in the lungs in spite of preexisting immunity. J. Virol. 81 17 (2007) 9443-9450
3. Brown T.A., Murphy B.R., Radl J., Haaijman J.J., and Mestecky J. Subclass distribution and molecular form of immunoglobulin A hemagglutinin antibodies in sera and nasal secretions after experimental secondary infection with influenza A virus in humans. J. Clin. Microbiol. 22 2 (1985) 259-264
4. Bukreyev A., and Collins P.L. Filovirus vaccines: what challenges are left?. Expert. Rev. Vaccines 9 1 (2010) 5-8
5. Bukreyev A., Lamirande E.W., Buchholz U.J., Vogel L.N., Elkins W.R., St Claire M., Murphy B.R., Subbarao K., and Collins P.L. Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Lancet 363 9427 (2004) 2122-2127
6. Bukreyev A., Yang L., Zaki S.R., Shieh W.J., Rollin P.E., Murphy B.R., Collins P.L., and Sanchez A. A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challenge. J. Virol. 80 5 (2006) 2267-2279
7. Bukreyev A., Rollin P.E., Tate M.K., Yang L., Zaki S.R., Shieh W.J., Murphy B.R., Collins P.L., and Sanchez A. Successful topical respiratory tract immunization of primates against Ebola virus. J. Virol. 81 12 (2007) 6379-6388
8. Bukreyev A., Marzi A., Feldmann F., Zhang L., Yang L., Ward J.M., Dorward D.W., Pickles R.J., Murphy B.R., Feldmann H., and Collins P.L. Chimeric human parainfluenza virus bearing the Ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against Ebola virus challenge. Virology 383 2 (2009) 348-361
9. Burlington D.B., Clements M.L., Meiklejohn G., Phelan M., and Murphy B.R. Hemagglutinin-specific antibody responses in immunoglobulin G, A, and M isotypes as measured by enzyme-linked immunosorbent assay after primary or secondary infection of humans with influenza A virus. Infect. Immun. 41 2 (1983) 540-545
10. Casimiro D.R., Chen L., Fu T.M., Evans R.K., Caulfield M.J., Davies M.E., Tang A., Chen M., Huang L., Harris V., Freed D.C., Wilson K.A., Dubey S., Zhu D.M., Nawrocki D., Mach H., Troutman R., Isopi L., Williams D., Hurni W., Xu Z., Smith J.G., Wang S., Liu X., Guan L., Long R., Trigona W., Heidecker G.J., Perry H.C., Persaud N., Toner T.J., Su Q., Liang X., Youil R., Chastain M., Bett A.J., Volkin D.B., Emini E.A., and Shiver J.W. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J. Virol. 77 11 (2003) 6305-6313
11. Claassen E.A., van der Kant P.A., Rychnavska Z.S., van Bleek G.M., Easton A.J., and van der Most R.G. Activation and inactivation of antiviral CD8 T cell responses during murine pneumovirus infection. J. Immunol. 175 10 (2005) 6597-6604
12. Collins P.L., and Crowe J.E.J. Respiratory syncytial virus and metapneumovirus. In: Knipe D.M., Howley P.M., Griffin D.E., Lamb R.A., Martin M.A., Roizman B., and Straus S.E. (Eds). Fields Virology. 5 ed. Vol. 2 (2007), Lippincott-Raven Publishers, Philadelphia 1601-1646 2 vols
13. Croyle M.A., Patel A., Tran K.N., Gray M., Zhang Y., Strong J.E., Feldmann H., and Kobinger G.P. Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice. PLoS ONE 3 10 (2008) e3548
14. DiNapoli J.M., Murphy B.R., Collins P.L., and Bukreyev A. Impairment of the CD8+ T cell response in lungs following infection with human respiratory syncytial virus is specific to the anatomical site rather than the virus, antigen, or route of infection. Virol. J. 5 (2008) 105
15. Dinapoli J.M., Nayak B., Yang L., Finneyfrock B.W., Cook A., Andersen H., Torres-Velez F., Murphy B.R., Samal S.K., Collins P.L., and Bukreyev A. Newcastle disease virus-vectored vaccines expressing the hemagglutinin or neuraminidase protein of H5N1 highly pathogenic avian influenza virus protect against virus challenge in monkeys. J. Virol. 84 3 (2010) 1489-1503
16. Durbin A.P., Skiadopoulos M.H., McAuliffe J.M., Riggs J.M., Surman S.R., Collins P.L., and Murphy B.R. Human parainfluenza virus type 3 (PIV3) expressing the hemagglutinin protein of measles virus provides a potential method for immunization against measles virus and PIV3 in early infancy. J. Virol. 74 15 (2000) 6821-6831
17. Fernandez Bracho J.G., and Roldan Fernandez S.G. [Early reactions in pupils vaccinated with an aerosol measles vaccine]. Salud Publica Mex. 32 6 (1990) 653-657
18. Fernandez-de Castro J., Kumate-Rodriguez J., Sepulveda J., Ramirez-Isunza J.M., and Valdespino-Gomez J.L. [Measles vaccination by the aerosol method in Mexico]. Salud Publica Mex. 39 1 (1997) 53-60
19. Fulton R.B., Olson M.R., and Varga S.M. Regulation of Cytokine Production by Virus-specific CD8 T Cells in the Lung. J. Virol. 82 16 (2008) 7799-7811
20. Garbutt M., Liebscher R., Wahl-Jensen V., Jones S., Moller P., Wagner R., Volchkov V., Klenk H.D., Feldmann H., and Stroher U. Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J. Virol. 78 10 (2004) 5458-5465
21. Geisbert T.W., Pushko P., Anderson K., Smith J., Davis K.J., and Jahrling P.B. Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg. Infect. Dis. 8 5 (2002) 503-507
22. Gray P.M., Arimilli S., Palmer E.M., Parks G.D., and Alexander-Miller M.A. Altered function in CD8+ T cells following paramyxovirus infection of the respiratory tract. J. Virol. 79 6 (2005) 3339-3349
23. Grayson M.H., Ramos M.S., Rohlfing M.M., Kitchens R., Wang H.D., Gould A., Agapov E., and Holtzman M.J. Controls for lung dendritic cell maturation and migration during respiratory viral infection. J. Immunol. 179 3 (2007) 1438-1448
24. Johnson E., Jaax N., White J., and Jahrling P. Lethal experimental infections of rhesus monkeys by aerosolized Ebola virus. Int. J. Exp. Pathol. 76 4 (1995) 227-236
25. Jones S.M., Feldmann H., Stroher U., Geisbert J.B., Fernando L., Grolla A., Klenk H.D., Sullivan N.J., Volchkov V.E., Fritz E.A., Daddario K.M., Hensley L.E., Jahrling P.B., and Geisbert T.W. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat. Med. 11 7 (2005) 786-790
26. Kanesa-Thasan N., Smucny J.J., Hoke C.H., Marks D.H., Konishi E., Kurane I., Tang D.B., Vaughn D.W., Mason P.W., and Shope R.E. Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus-poxvirus vaccines in vaccinia-nonimmune and vaccinia-immune humans. Vaccine 19 4-5 (2000) 483-491
27. Karron R.A., Belshe R.B., Wright P.F., Thumar B., Burns B., Newman F., Cannon J.C., Thompson J., Tsai T., Paschalis M., Wu S.L., Mitcho Y., Hackell J., Murphy B.R., and Tatem J.M. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants. Pediatr. Infect. Dis. J. 22 5 (2003) 394-405
28. Karron R.A., and Collins P.L. Parainfluenza viruses. In: Knipe D.M., Howley P.M., Griffin D.E., Lamb R.A., Martin M.A., Roizman B., and Straus S.E. (Eds). Fields Virology. 5 ed 1. 2 vols (2007), Lippincott-Raven Publishers, Philadelphia
29. Kuhn J.H. In: Calisher C.H. (Ed). Filoviruses. 1 ed. (2008), Springer, Wien New York
30. Legge K.L., and Braciale T.J. Accelerated migration of respiratory dendritic cells to the regional lymph nodes is limited to the early phase of pulmonary infection. Immunity 18 2 (2003) 265-277
31. Lemckert A.A., Sumida S.M., Holterman L., Vogels R., Truitt D.M., Lynch D.M., Nanda A., Ewald B.A., Gorgone D.A., Lifton M.A., Goudsmit J., Havenga M.J., and Barouch D.H. Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity. J. Virol. 79 15 (2005) 9694-9701
32. Lukens M.V., Kruijsen D., Coenjaerts F.E., Kimpen J.L., and van Bleek G.M. Respiratory syncytial virus-induced activation and migration of respiratory dendritic cells and subsequent antigen presentation in the lung-draining lymph node. J. Virol. 83 14 (2009) 7235-7243
33. McCoy K., Tatsis N., Korioth-Schmitz B., Lasaro M.O., Hensley S.E., Lin S.W., Li Y., Giles-Davis W., Cun A., Zhou D., Xiang Z., Letvin N.L., and Ertl H.C. Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors. J. Virol. 81 12 (2007) 6594-6604
34. Reed L.J., and Muench H. A simple method of estimating fifty per cent endpoints. Am. J. Epidemiol. 27 (1938) 493-497
35. Sanchez A., Geisbert T.W., and Feldmann H. Filoviridae: Marburg and Ebola viruses. In: Knipe D.M., Howley P.M., Griffin D.E., Lamb R.A., Martin M.A., Roizman B., and Straus S.E. (Eds). Fields Virology. 5 ed. 1. 2 vols (2007), Lippincott-Raven Publishers, Philadelphia
36. Sharpe S., Polyanskaya N., Dennis M., Sutter G., Hanke T., Erfle V., Hirsch V., and Cranage M. Induction of simian immunodeficiency virus (SIV)-specific CTL in rhesus macaques by vaccination with modified vaccinia virus Ankara expressing SIV transgenes: influence of pre-existing anti-vector immunity. J. Gen. Virol. 82 Pt 9 (2001) 2215-2223
37. Sullivan N.J., Martin J.E., Graham B.S., and Nabel G.J. Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nat. Rev. Microbiol. 7 5 (2009) 393-400
38. Sullivan N.J., Sanchez A., Rollin P.E., Yang Z.Y., and Nabel G.J. Development of a preventive vaccine for Ebola virus infection in primates. Nature 408 6812 (2000) 605-609
39. Tao T., Davoodi F., Cho C.J., Skiadopoulos M.H., Durbin A.P., Collins P.L., and Murphy B.R. A live attenuated recombinant chimeric parainfluenza virus (PIV) candidate vaccine containing the hemagglutinin-neuraminidase and fusion glycoproteins of PIV1 and the remaining proteins from PIV3 induces resistance to PIV1 even in animals immune to PIV3. Vaccine 18 14 (2000) 1359-1366
40. Vallbracht S., Unsold H., and Ehl S. Functional impairment of cytotoxic T cells in the lung airways following respiratory virus infections. Eur. J. Immunol. 36 6 (2006) 1434-1442
41. van Wyke Coelingh K.L., Winter C., and Murphy B.R. Antigenic variation in the hemagglutinin-neuraminidase protein of human parainfluenza type 3 virus. Virology 143 2 (1985) 569-582
42. Yang L., Sanchez A., Ward J.M., Murphy B.R., Collins P.L., and Bukreyev A. A paramyxovirus-vectored intranasal vaccine against Ebola virus is immunogenic in vector-immune animals. Virology 377 2 (2008) 255-264
43. Yang Z.Y., Wyatt L.S., Kong W.P., Moodie Z., Moss B., and Nabel G.J. Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J. Virol. 77 1 (2003) 799-803